This review highlights the critical importance of optimizing the timing of stem cell therapy following myocardial infarction, suggesting the first month post-MI as the most promising therapeutic window.
Authors
No takes yet. Share an insight, caveat, or question.
Timing within first month post-MI merits testing in trials; leaves open optimal dosing and route.
Kasper W. ter Horst (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: